CanCure, LLC
dba CanZx Biotherapeutics
Tel: (206) 353-7538
First-in-Class Cancer Immunotherapeutics
New Generation of Cancer-Immunotherapy:
Empower your own immune system to fight cancer
”Our goal is to make immunotherapy benefit the majority of cancer patients, not just a few”
Jennifer Wu, PhD. President.
”Our goal is to make immunotherapy benefit the majority of cancer patients, not just a few”
Jennifer Wu, PhD. President.
September 2018
CanCure was selected to present at Ignite Illinois Technology Showcase on September 27.
August 2018
CanCure Founder, Dr. Wu, Presented at Iummuno-Oncology Summit Annual meeting in Boston.
CHI-IO summit Boston 2018_Wu.pdf
November 2017
CanCure Founder, Dr. Wu, presented SITC (Society for Immunotherapy of Cancer) Annual Meeting in MD “Antibody-mediated clearance of soluble MIC significantly enhances response to CTLA4 blockade and reduces therapy-induced colitis “.
The presentation was in “SITC 2017 Scientific Highlights - Nov. 10” http://blog.sitcancer.org/2017/11/sitc-2017-scientific-highlights-nov-10.html
October 2017
CuraB-10 US Patent of Composition of Matter and Utility was granted.
CanCure LLC was selected by NIH NCI small business initiatives to showcase in Life Science Summit in New York in October 31-Nov. 01.
March 2017
CanCure LLC was accepted to MIH/NCI ICorp program
January 2017
CanCure received $50,000 match STTR Phase I award from SCRA- SC Launch Program.
November, 2016
CanCure Founder and CSO, Dr. Jennnifer Wu, gave an oral presentation at the Society for Immunotherapy of Cancer (SITC)'s 31st Annual Meeting at the Gaylord National Hotel & Convention Center in National Harbor, MD.
2016 SITC annual meeting Article.pdf
October, 2016
CanCure Founder and CSO, Dr. Jennnifer Wu, was featured in Research News by the Medical University of South Carolina. Visit:
http://academicdepartments.musc.edu/newscenter/2016/Researcher-leading-the-field-in-cancer-immunotherapy/
September, 2016
CanCure Received NIH/NCI STTR Phase I small business award to advance the CanCure Leading First-in-class cancer immunotherapeutic leading antibody CuraB-10 for clinical application.